Janocko L E, Lucke J F, Groft D W, Brown K A, Smith C A, Pollice A A, Singh S G, Yakulis R, Hartsock R J, Shackney S E
Laboratory of Cancer Cell Biology and Genetics, Allegheny-Singer Research Institute, Pittsburgh, PA 15212-4772, USA.
Cytometry. 1995 Sep 1;21(1):18-22. doi: 10.1002/cyto.990210106.
Studies of amplification and/or overexpression of c-myc, HER-2/neu, and H-ras in breast cancer have shown that each is associated with a poor prognosis. The purpose of this study was to explore the possibility that there is a preferred sequence of amplification of these oncogenes in breast cancer. The frequencies of amplification and patterns of co-amplification of c-myc, HER-2/neu, and H-ras were studied in a group of 84 breast cancers. The data suggested a preferred sequence of amplification that consisted of c-myc amplification-HER-2/neu amplification-H-ras amplification. This model was supported by loglinear analysis. In addition, the levels of amplification of JC-A, a DNA fragment newly isolated from a patient with advanced breast cancer, were studied in 61 of these cases. The data suggested that JC-A amplification occurred early. Loglinear analysis supported a model in which JC-A amplification occurred either before or after c-myc amplification but was unrelated to Her-2/neu or ras amplification.
对乳腺癌中c-myc、HER-2/neu和H-ras基因的扩增及/或过表达研究表明，每种基因都与不良预后相关。本研究的目的是探讨乳腺癌中这些癌基因存在优先扩增顺序的可能性。在一组84例乳腺癌中研究了c-myc、HER-2/neu和H-ras基因的扩增频率及共扩增模式。数据提示了一个优先扩增顺序，即c-myc扩增-HER-2/neu扩增-H-ras扩增。该模型得到对数线性分析的支持。此外，在其中61例病例中研究了从一名晚期乳腺癌患者新分离出的DNA片段JC-A的扩增水平。数据提示JC-A扩增发生较早。对数线性分析支持这样一个模型，即JC-A扩增发生在c-myc扩增之前或之后，但与Her-2/neu或ras扩增无关。
